Table 1 Clinical characteristics and expression of CLASP2 and EMT markers mRNA
Variables | Patients (n) | Progression within 2 years | ||
|---|---|---|---|---|
No (n) | Yes (n) | P | ||
Total (%) | 102 | 68 | 34 | |
Gender | ||||
Male | 72 | 52 | 20 | 0.11 |
Female | 30 | 16 | 14 | |
Age(years) | ||||
< 60 | 38 | 27 | 11 | 0.61 |
> 60 | 64 | 41 | 23 | |
Intravesical instillation | ||||
Immediate | 29 | 22 | 7 | 0.31 |
Maintenance | 73 | 46 | 27 | |
Tumor stage | ||||
Ta | 34 | 25 | 9 | 0.41 |
T1 | 68 | 43 | 25 | |
Tumor grade | ||||
G1 | 33 | 26 | 7 | 0.04 |
G2 | 49 | 33 | 16 | |
G3 | 20 | 9 | 11 | |
Concomitant CIS | ||||
Yes | 3 | 1 | 2 | 0.26 |
No | 99 | 67 | 32 | |
Tumor size (cm) | ||||
< 3 | 59 | 44 | 15 | 0.07 |
> 3 | 43 | 24 | 19 | |
Multiplicity | ||||
Single | 44 | 34 | 10 | 0.06 |
Multiple | 58 | 34 | 24 | |
CLASP2 mRNA (tumor) | ||||
High | 30 | 6 | 24 | <0.01 |
Low | 72 | 62 | 10 | |
CLASP2 mRNA (urine) | ||||
High | 55 | 24 | 31 | < 0.01 |
Low | 47 | 44 | 3 | |
E-cadherin mRNA (tumor) | ||||
High | 62 | 52 | 10 | < 0.01 |
Low | 40 | 16 | 24 | |
E-cadherin mRNA (urine) | ||||
High | 60 | 54 | 6 | < 0.01 |
Low | 42 | 14 | 28 | |
Vimentin mRNA (tumor) | ||||
High | 55 | 31 | 24 | 0.16 |
Low | 47 | 37 | 10 | |
Vimentin mRNA (urine) | ||||
High | 62 | 36 | 26 | 0.03 |
Low | 40 | 32 | 8 | |